• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

AbbVie - Articles and news items

grazoprevir/elbasvir

AbbVie receives FDA approval for new Hepatitis C drug

Industry news / 27 July 2016 / Niamh Louise Marriott, Digital Content Producer

US FDA has approved Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of chronic genotype 1 (GT1) hepatitis C…

sb5

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

Industry news / 18 July 2016 / Victoria White, Digital Content Producer

At an estimated $4billion a year, the reference product, Humira, is among the European Union’s largest single drug expenditures…

fingernail psoriasis

AbbVie announces study data for Humira in fingernail psoriasis

Industry news / 7 July 2016 / Victoria White, Digital Content Producer

Nearly half of adult patients treated with Humira achieved at least a 75% improvement in their fingernail psoriasis compared to patients receiving placebo…

zinbryta

EC grants marketing authorisation for Zinbryta in multiple sclerosis

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

The approval of Zinbryta is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS…

adalimumab

FDA approves adalimumab for the treatment of non-infectious uveitis

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

Adalimumab is now the only FDA-approved non-corticosteroid therapy available for adults with non‑infectious intermediate, posterior and panuveitis…

nice

NICE recommends five drugs to treat four different conditions

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

NICE has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS…

venetoclax

Venetoclax shown to be effective in CLL patients who relapse or are refractory

Industry news / 10 June 2016 /

New data show promising results for venetoclax in patients with chronic lymphocytic leukaemia who have relapsed or become refractory (R/R) to treatment…

abbvie

AbbVie tops the RepTrak ranking for most reputable pharma company in the UK

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

Reputation Institute has announced that AbbVie, Sanofi and Novo Nordisk top the RepTrak ranking of the most reputable pharmaceutical companies in the UK…

empliciti

EC approves Empliciti as combination therapy for multiple myeloma

Industry news / 12 May 2016 / Victoria White, Digital Content Producer

Empliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy…

adalimumab

NICE recommends adalimumab for hidradenitis suppurativa

Industry news / 6 May 2016 / Victoria White, Digital Content Producer

AbbVie’s Humira (adalimumab) is the first treatment option licensed for active moderate to severe hidradenitis suppurativa…

abt-493

AbbVie presents data for ABT-493 and ABT-530 regimen in HCV

Industry news / 18 April 2016 / Victoria White, Digital Content Producer

With eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12…

Viekirax

AbbVie presents real-world data for Viekirax + Exviera in HCV

Industry news / 15 April 2016 / Victoria White, Digital Content Producer

AbbVie has announced new real-world data for Viekirax and Exviera, showing 96% of GT1 HCV patients and 100% of GT4 patients achieved SVR12…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +